Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Current Urology Reports
Erschienen in: Current Urology Reports 11/2018

01.11.2018 | Lower Urinary Tract Symptoms & Voiding Dysfunction (J Sandhu, Section Editor)

Management of Overactive Bladder in Older Women

verfasst von: Toya S. Pratt, Anne M. Suskind

Erschienen in: Current Urology Reports | Ausgabe 11/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose of review:

This review will highlight our current understanding of age-related changes in bladder function and propose important clinical considerations in the management of overactive bladder (OAB) specific to older women.

Recent findings:

Frailty, functional and cognitive impairment, multimorbidity, polypharmacy, estrogen deficiency, and remaining life expectancy are important clinical factors to consider and may impact OAB symptom management in older women. Third-line therapies, particularly PTNS, may be preferable over second-line therapy in some cases.

Summary:

Due to the complexity within this population, the standard treatment algorithms may not be applicable, thus a broader, more holistic focus is recommended when managing OAB in older women.
Literatur
1.
Sexton C, Coyne K, Thompson C, et al. Prevalence and effect on health-related quality of life of overactive bladder in older Americans: results from the epidemiology of lower urinary tract symptoms study. J Am Geriatr Soc. 2011;59:1465–70.CrossRefPubMed
2.
Brown JS, Vittinghoff E, Wyman J, et al. Urinary incontinence: does it increase risk for fall and fracture? J Am Geriatr Soc. 2000;48:721–5.CrossRefPubMed
3.
Coyne KS, Sexton CC, Kopp Z, et al. Assessing patients’ descriptions of lower urinary tract symptoms (LUTS) and perspectives on treatment outcomes: results of qualitative research. IJCP. 2010:1–37.
4.
Ganz ML, Smalarz AM, Krupski TL, Anger JT, Hu JC, Wittrup-Jensen KU, et al. Economic costs of overactive bladder in the United States. Urology. 2010;75(3):526–32.CrossRefPubMed
5.
Gormley EA, Lightner DJ, Burgio KL, Chai TC, Clemens JQ, Culkin DJ, Das AK, Foster Jr HE, Scarpero HM, Tessier CD, Vasavada SP American Urological Association; Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline J Urol 2012;188(6 Suppl):2455–2463.
6.
• Gormely E, Lightner D, Faraday M, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment. J Urol. 2015;193:1572–80. An important update including relevant newly published literature for the diagnosis and treatment of patients with non-neurogenic overactive bladder. CrossRef
7.
Tadic SD, Griffiths D, Schaefer W, Murrin A, Clarkson B, Resnick NM. Brain activity underlying impaired continence control in older women with overactive bladder. Neurourol Urodyn. 2012 Jun;31(5):652–658.CrossRefPubMedPubMedCentral
8.
Ketai LH, Komesu YM, Dodd AB et al. Urgency urinary incontinence and the interoceptive network: a functional magnetic resonance imaging study. Am J Obstet Gynecol. 2016;215(4):449.e1–449.e17.CrossRefPubMedPubMedCentral
9.
Brading A, Symes S. Ischemia as an etiological factor in bladder instability: implications for therapy. Adv Exp Med Biol. 2003;503:255–69.
10.
Yoshida M, Miyamae K, Iwashita H, Otani M, Inadome A. Management of detrusor dysfunction in the elderly: changes in acetylcholine and adenosine triphosphate release during aging. Urology. 2004;63(3 Suppl 1):17–23. Review CrossRef
11.
Tincello D, Taylor A, Spurling S, et al. Receptor isoforms that mediate estrogen and progesterone action in the female lower urinary tract. J Urol. 2009;181:1474–82.CrossRefPubMed
12.
Iosif S, Batra S, Ek A, et al. Estrogens receptors in the human female lower urinary tract. Am J Obstet Gynaecol. 1981;141:817–20.CrossRef
13.
Batra SC, Iosif LS. Progesterone receptors in the female urinary tract. J Urol. 1987;138:130–4.CrossRef
14.
• Robinson D, Cardoza L, Milsom I et al. Oestrogens and overactive bladder. Neurourol Urodynam.2014.33:1086-1091 Interesting review article on the evidence for the role of estrogen therapy in the management of OAB.
15.
16.
Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56(3):M146–56.CrossRef
17.
Suskind AM, Quanstrom K, Zhao S, Bridge M, Walter LC, Neuhaus J, et al. Overactive bladder is strongly associated with frailty in older individuals. Urology. 2017;106:26–31.CrossRefPubMedPubMedCentral
18.
Jensen J, Lundin-Olsson L, Nyberg L, et al. Falls among frail older people in residential care. Scand J Public Health. 2002;30(1):54–61.CrossRefPubMed
19.
Plassman BL, Langa KM, Fisher GG, Heeringa SG, Weir DR, Ofstedal MB, et al. Prevalence of dementia in the United States: the aging, demographics, and memory study. Neuroepidemiology. 2007;29(1–2):125–32.CrossRefPubMedPubMedCentral
20.
Jekel K, Damian M, Wattmo C, et al. Mild cognitive impairment and deficits in instrumental activities of daily living: a systematic review. Alzheimers Res Ther. 2015:7–17.
21.
Gold D. An examination of instrumental activities of daily living assessment in older adults and mild cognitive impairment. J Clin Exp Neuropsychol. 2012;34(1):11–34.CrossRefPubMed
22.
Ouslander JG, Shih YT, Malone-Lee J, Luber K. Overactive bladder: special considerations in the geriatric population. Am J Manag Care. 2000;6(11 Suppl):S599–606. Review PubMed
23.
Fayyad A, Hill S, Jones G. Prevalence and risk factors for bothersome lower urinary tract symptoms in women with diabetes mellitus from hospital-based diabetes clinic. Int Urogynecol J. 2009;20:1339–44.CrossRef
24.
Yuan Z, Tang Z, Changxiao H, et al. Diabetic cystopathy: a review. J Diabetes. 2015;7:442–7.CrossRefPubMed
25.
Boudreau D, Yu O, Gray S, et al. Concomitant use of cholinesterase inhibitors and anticholingerics: prevalence and outcomes. J Am Geriatr Soc. 2011;59:2069–76.CrossRefPubMed
26.
Maeda T, Tomita M, Nakazawa A, et al. Female functional constipation is associated with overactive bladder symptoms and urinary incontinence. Biomed Res Int. 2017;2138073
27.
Morin L, Johnell K, Laroche ML, Fastbom J, Wastesson JW. The epidemiology of polypharmacy in older adults: register-based prospective cohort study. Clin Epidemiol. 2018;10:289–98.CrossRefPubMedPubMedCentral
28.
Schneidinger CS, Umek W, Böhmdorfer B. The problem of polypharmacy in female patients with overactive bladders - cross-sectional study in a specialist outpatient department. Geburtshilfe Frauenheilkd. 2016 Dec;76(12).CrossRefPubMedPubMedCentral
29.
By the American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2015;63(11):2227–46.
30.
Iosif C, Bekassy Z. Prevalence of genitourinary symptoms in the late menopause. Acta Obstet Gynaecol Scan. 1984;63:257–60.CrossRef
31.
Batra S, Andersson K. Estrogen-induced changes in muscarinic receptor density and contractile responses in the female rat urinary bladder. Acta Physiol Scand. 1989;137:135–41.CrossRefPubMed
32.
Shenfield O, Blackmore P, Morgan C, et al. Rapid effects of estriol and progesterone on tone and spontaneous rhythmic contractions of the rabbit bladder. Neurourol Urodyn. 1998;17:408–9.
33.
Griebling TL, Liao Z, Smith PG. Systemic and topical hormone therapies reduce vaginal innervations density in postmenopausal women. Menopause. 2010;19:630–5.CrossRef
34.
Tandir Y, Ercan F, Tarcan T. Exogenous testosterone and estrogen affect bladder tissue contractility and histomorphology differently in rat ovariectomy model. J Sex Med. 2011;8:1626–37.CrossRef
35.
Benness C, Wise BG, Cutner A, et al. Does low dose vaginal oestradiol improve frequency and urgency in postmenopausal women. Int Urogynaecol J. 1992;3:281.
36.
Eriksen PS, Rasmussen H. Low dose 17b-oestradiol vaginal tablets in the treatment of atrophic vaginitis: a double-blind placebo controlled study. Eur J Obstet Gynaecol Reprod Biol. 1992;44:137–44.CrossRef
37.
Tseng LH, Wang AC, Chang YL, Soong YK, Lloyd LK, Ko YJ. Randomized comparison of tolterodine with vaginal estrogen cream versus tolterodine alone for the treatment of postmenopausal women with overactive bladder syndrome. Neurourol Urodyn. 2009;28:47–51.CrossRefPubMed
38.
Serati M, Salvatore S, Uccella S, Cardozo L, Bolis P. Is there a synergistic effect of topical estrogens when administered with antimuscarinics in the treatment of symptomatic detrusor overactivity? Eur Urol. 2009;55:713–9.CrossRefPubMed
39.
Nelken RS, Ozel BZ, Leegant AR, et al. Randomised trial of oestradiol vaginal ring versus oral oxybutynin for the treatment of overactive bladder. Menopause. 2011;18:962–6.CrossRefPubMed
40.
Cody JD, Richardson K, Moehrer B, et al. Estrogen therapy for urinary incontinence in postmenopausal women. Cochrane Database Syst Rev 2009; Issue 4. Art. No: CD001405.
41.
Health, United States, 2016: with chartbook on long-term trends in health. Centers for disease control and prevention. National center for health statistics. 2017.
42.
Vinsnes AG, Helbostad JL, Nyronning S, et al. Effect of physical training on urinary incontinence: a randomized parallel group trial in nursing homes. Clin Interv Aging. 2012;7:45–50.CrossRefPubMedPubMedCentral
43.
Tak EC, van Hespen A, van Dommelen P, et al. Does improved functional performance help to reduce urinary incontinence in institutionalized older women? A multicenter randomized clinical trial. BMC Geriatr. 2012;12:51.CrossRefPubMedPubMedCentral
44.
Ouslander JG, Griffiths PC, McConnell E, Riolo L, Kutner M, Schnelle J. Functional incidental training: a randomized, controlled, crossover trial in Veterans Affairs nursing homes. J Am Geriatr Soc. 2005;53:1091–100.CrossRefPubMed
45.
Schnelle JF, MacRae PG, Ouslander JG, et al. Functional incidental training, mobility performance, and incontinence care with nursing home residents. J Am Geriatr Soc. 1995;43:1356–62.CrossRefPubMed
46.
Talley KC, Wyman JF, Bronas U, et al. Defeating urinary incontinence with exercise training: results of a pilot study in frail older women. J Am Geriatr Soc. 2017;65(6):1321–7.CrossRefPubMedPubMedCentral
47.
Burgio KL, Goode PS, Locher JL, Umlauf MG, Roth DL, Richter HE, et al. Behavioral training with and without biofeedback in the treatment of urge incontinence in older women: a randomized controlled trial. JAMA. 2002 Nov 13;288(18):2293–9.CrossRefPubMed
48.
Griffiths D, Clarkson B, Tadic SD, Resnick NM. Brain mechanisms underlying urge incontinence and its response to pelvic floor muscle training. J Urol. 2015;194(3):708–15.CrossRefPubMedPubMedCentral
49.
Hooper L, Abdelhamid A, Attreed NJ, et al. Clinical symptoms, signs and tests for identification of impending and current water-loss dehydration in older people. Cochrane Database Syst Rev. 2015;4:CD009647.
50.
Wagg A. Antimuscarinic treatment in overactive bladder: special considerations in elderly patients. Drugs Aging. 2012;29(7):539–48.CrossRefPubMed
51.
Carriere I, Fourrier-Reglat A, Dartigues J, et al. Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population: the 3-city study. Arch Intern Med. 2009;169(14):1317–24.CrossRefPubMedPubMedCentral
52.
Fox C, Richardson K, Maidman I, et al. Anticholinergic medication and use and cognitive impairment in the older population: the medical research council cognitive function and aging study. J Am Geriatr Soc. 2011;59(8):1477–83.CrossRefPubMed
53.
McFerren S, Gomelsky A. Treatment of overactive bladder in the elderly female: the case for trospium, oxybutynin, fesoterodine and darifenacin. Drugs Aging. 2015;32:809–19.CrossRefPubMed
54.
Salahudeen MS, Duffull SB, Nishtala PS. Anticholinergic burden quantified by anticholinergic risk scales and adverse outcomes in older people: a systematic review. BMC Geriatr. 2015 Mar 25;15:31.CrossRefPubMedPubMedCentral
55.
Boustani M, Campbell N, Munger S, Maidment I, Fox C. Impact of anticholinergics on the aging brain: a review and practical application. Aging Health. 2008;4(3):311–20.CrossRef
56.
DuBeau C, Kraus S, Griebling T, et al. Effect of fesoterodine in vulunerable elderly subjects with urgency incontinence: a double-blind, placebo-controlled trial. J Uro. 2014;191:395–404.CrossRef
57.
Wagg A, Khullar V, Marschall-Kehrel D, Michel MC, Oelke M, Darekar A, et al. Flexible-dose fesoterodine in elderly adults with overactive bladder: results of the randomized, double-blind, placebo-controlled study of fesoterodine in an aging population. J Am Geriatr Soc. 2013;61:185–93.CrossRefPubMed
58.
• Geller EJ, Dumond JB, Bowling JM et al. Effect of trospium chloride on cognitive function in women aged 50 and older: a randomized trial. Female Pelvic Med Reconstr Surg. 2017;23(2):118–123 Randomized double-blind placebo-controlled trial aimed to investigate the effect of trospium chloride on cognitive function in postmenopausal women treated for OAB with no changes in cognitive function found between those taking trospium and placebo. CrossRef
59.
Rosa G, Ferrero S, Nitti V, et al. Cardiovascular safety of B3-adrenoceptor agonists for the treatment of patients with overactive bladder. Eur Urol. 2016;69:311–23.CrossRefPubMed
60.
Yamaguchi O, Chapple CR. Beta3-adrenoceptors in urinary bladder. Neurourol Urodyn. 2007;26(6):752–6.CrossRefPubMed
61.
Burton C, Sajja A, Latthe PM. Effectiveness of percutaneous posterior tibial nerve stimulation for overactive bladder: a systematic review and meta-analysis. Neurourol Urodyn. 2012;31(8):1206–16.CrossRefPubMed
62.
Amundsen CL, Webster GD. Sacral neuromodulation in an older, urge incontinent population. Am J Obstet Gynecol. 2002;187(6):1462–5.CrossRefPubMed
63.
• Faris A, Gill B, Pizarro-Berdichevsky J. Impact of age and comorbidities on use of sacral neuromodulation. J Urol.2017;198(1):161–166 This study challenges the existing literature regarding age and SNS outcomes, suggesting that age alone should not be considered a limiting factory in SNS and can be modestly protective against device revision. CrossRefPubMed
64.
Miotla P, Cartwright R, Skorupska K, Bogusiewicz M, Markut-Miotla E, Futyma K, et al. Urinary retention in female OAB after intravesical Botox injection: who is really at risk. Int Urogynecol J. 2017;28(6):845–50.CrossRefPubMed
65.
• Komesu Y, Amundsen C, Richter H, et al. Refractory urgency urinary incontinence treatment in women: impact of age on outcomes and complications. Am J Obstet Gynecol.2018;218.e1–9 Interesting planned secondary analysis of a multicenter, randomized trial on treatment efficacy and adverse events in women treated with onabotulinumtoxinA or SNS and stratified by age.
66.
Liao C, Kuo H. Increased risk of large post-void residual urine and decreased long-term success rate after intravesical onabotulinumtoxinA injection for refractory idiopathic detrusor overactivity. J Urol. 2013;189:1804–10.CrossRefPubMed
67.
Owen RK, Abrams KR, Mayne C, Slack M, Tincello DG. Patient factors associated with onabotulinum toxin A treatment outcome in women with detrusor overactivity. Neurourol Urodyn. 2017 Feb;36(2):426–31.CrossRefPubMed
Metadaten
Titel
Management of Overactive Bladder in Older Women
verfasst von
Toya S. Pratt
Anne M. Suskind
Publikationsdatum
01.11.2018
Verlag
Springer US
Erschienen in
Current Urology Reports / Ausgabe 11/2018
Print ISSN: 1527-2737
Elektronische ISSN: 1534-6285
DOI
https://doi.org/10.1007/s11934-018-0845-5

Weitere Artikel der Ausgabe 11/2018

Current Urology Reports 11/2018 Zur Ausgabe

Lower Urinary Tract Symptoms & Voiding Dysfunction (J Sandhu, Section Editor)

What Is the Role of Additional Pharmacotherapy and Neuromodulation in Patients with Marginal Benefit from Botulinum Toxin Injection?

Lower Urinary Tract Symptoms & Voiding Dysfunction (J Sandhu, Section Editor)

Management of Chronic Prostatitis (CP)

New Imaging Techniques (S Rais-Bahrami and K Porter, Section Editors)

Use of MR Urography in Pediatric Patients

Lower Urinary Tract Symptoms & Voiding Dysfunction (J Sandhu, Section Editor)

Complications of Botox and their Management

New Imaging Techniques (S Rais-Bahrami and K Porter, Section Editors)

Advanced Imaging for the Diagnosis and Treatment of Coexistent Renal and Müllerian Abnormalities

Lower Urinary Tract Symptoms & Voiding Dysfunction (J Sandhu, Section Editor)

Recurrent Urinary Tract Infections in Females and the Overlap with Overactive Bladder

Neu im Fachgebiet Urologie

18.04.2024 | Infertilität | Nachrichten

Viele Ärzte haben Probleme mit der Zeugungsfähigkeit

17.04.2024 | Postoperative nausea and vomiting | Nachrichten

Hochrisiko-Eingriffe für postoperative Übelkeit

10.04.2024 | PSA-Screening | Nachrichten

Einladung zum PSA-Screening senkt die Krebssterblichkeit

08.04.2024 | Andrologie | Nachrichten

Wie toxische Männlichkeit der Gesundheit von Männern schadet
weitere anzeigen

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen